6:20 AM ET
8-K
Research Collaboration
Perspective Therapeutics Research Collaboration with Merck
Perspective Therapeutics has entered into a clinical trial collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda. The combination will be tested in an ongoing Phase 1/2a study for FAP-alpha positive solid tumors, with Perspective sponsoring the study and Merck providing pembrolizumab at no cost.
- Counterparty
- Merck